Gadolinium Toxicity
Conditions
Keywords
Liver transplantation, Renal transplantation, Pancreas transplantation
Brief summary
Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known of its toxicity outside of patients with reduced renal function.
Detailed description
Gadolinium contrast is administered to patients during MRI imaging. Recently, the investigators have observed potential gadolinium toxicity in some patients. To investigate this, the investigators propose to collect clinical data and lab data obtained as a part of clinical care. The investigators also plan to obtain 25 cc of peripheral blood at 2-4 weeks, 4-6 weeks and again at 3 months to identify unique monocyte signatures, gene polymorphisms, and to quantitate circulating fibrocytes (in fresh blood and after culture). Plan to enroll 15 patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents, 15 non-transplant patients exposed to gadolinium contrast and 30 age- and sex-matched healthy controls not exposed to gadolinium contrast.
Interventions
DRUGGadolinium contrast dye
Gadolinium contrast dye administered during MRI
Sponsors
University of Virginia
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Renal, pancreas or liver transplant OR those without organ transplant OR controls * Age 18-70 * Both gender * Exposure to gadolinium contrast agents (no exposure in controls) * Have had a transplant, have had a contrast dye with an MRI * Have not had a transplant and have had a contrast dye with an MRI * Healthy person who has not had an MRI or gadolinium for any other reason.
Exclusion criteria
* End stage kidney disease or Stage 5 * Previous diagnosis of Nephrogenic Systemic Fibrosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| total number of circulating fibrocytes | 2-4 weeks | 2-4 weeks after gadolinium contrast exposure |
Countries
United States
Contacts
Primary ContactSundararaman Swaminathan, MD
Outcome results
None listed